Psoriatic arthritis: Advances in therapy

International Journal of Advances in Rheumatology

Volumn 9, Issue 2, 2011, Pages 45-55

  Ceponis, Arnold ^a   Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; USTEKINUMAB;

ARTHRITIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; DACTYLITIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; EVIDENCE BASED MEDICINE; FATIGUE; HUMAN; INTERSTITIAL LUNG DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN; PHYSICAL CAPACITY; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION;

EID: 84863856859     PISSN: 1478856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
2. Vander Cruyssen B, Hoffman IE, Zmierczak H et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005;64:1145-9.
3. Hanly JG, Russell ML, Gladman DD. Psoriatic spondyloarthropathy: a long-term prospective study. Ann Rheum Dis 1988;47:386-93.
4. Chandran V, Barrett J, Schentag CT et al. Axial psoriatic arthritis: update on a longterm prospective study. J Rheumatol 2009;36:2744-50.
5. Kaçar C, Sezer I, Kocabaş H et al. Sacroiliac joint involvement in psoriasis. Rheumatol Int 2010;30:1263-6.
6. Taylor W, Gladman D, Helliwell P et al.; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
7. Chandran V, Schentag CT, Gladman DD. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 2007;57:1560-3. (Pubitemid 350308858)
8. Kaipiainen-Seppanen O. Incidence of psoriatic arthritis in Finland. Br J Rheumatol 1996;35:1289-91.
9. Shbeeb M, Uramoto KM, Gibson LE et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-50. (Pubitemid 30262512)
10. Hukuda S, Minami M, Saito T et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001;28:554-9. (Pubitemid 32202659)
11. Savolainen E, Kaipiainen-Seppanen O, Kroger L et al. Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. J Rheumatol 2003;30:2460-8. (Pubitemid 37413909)
12. Gelfand J, Gladman D, Mease P et al. Epidemiology of psoriatic arthritis in the United States population. J Am Acad Dermatol 2005;53:573.
13. Wilson FC, Icen M, Crowson CS et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol 2009;36:361-7.
14. Taylor WJ, Zmierczac HG, Helliwell PS. Problems with the definition of axial and peripheral disease patterns in psoriatic arthritis. J Rheumatol 2005;32:974-7. (Pubitemid 40828064)
15. Kane D, Statfford L, Bresnihan B et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42:1460-8. (Pubitemid 37508919)
16. Gladman DD, Helliwell P, Mease PJ et al. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004;50:24-35. (Pubitemid 38084284)
17. Mease PJ, Antoni CE, Gladman DD et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl. 2):ii49-ii54. (Pubitemid 40288522)
18. Ritchlin CT, Kavanaugh A, Gladman DD et al.; Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
19. Schoels M, Aletaha D, Funovits J et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441-7.
20. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48-53.
21. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010;62:965-9.
22. Mumtaz A,Gallagher P, Kirby B et al . Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2010;70:272-7.
23. Williamson L, Dockerty JL, Dalbeth N et al. Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. Rheumatology (Oxford) 2004;43:85-8. (Pubitemid 38088373)
24. Guglielmi G, Scalzo G, Cascavilla A et al. Imaging of the sacroiliac joint involvement in seronegative spondylarthropathies. Clin Rheumatol 2009;28:1007-19.
25. Bennett AN, McGonagle D, O'Connor P et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographilcally evident ankylosing spondylitis at eight years. Arhritis Rheum 2008;58:3413-8.
26. Østergaard M, McQueen F, Wiell C et al. The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA hands. J Rheumatol 2009;36:816-24.
27. Mease P, Genovese MC, Gladstein G et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, Phase II trial. Arthritis Rheum 2011;63:939-48.
28. Appel H, Hermann KG, Althoff CE et al. Whole-body magnetic resonance imaging evaluation of widespread inflammatory lesions in a patient with ankylosing spondylitis before and after 1 year of treatment with infliximab. J Rheumatol 2007;34:2497-8. (Pubitemid 350230680)
29. Weckbach S. Whole-body MR imaging for patients with rheumatism. Eur J Radiol 2009;70:431-41.
30. Hennigan S, Du J, Chung C et al. Evaluation of enthesopathy in psoriatic arthritis using a 3 Tesla MRI and using novel ultrashort time echo (UTE) pulse sequences for imaging. Arthritis Rheum 2007;56(Suppl.):F27:5 (Abstract 565).
31. Klauser AS, De Zordo T, Bellman-Weiler R et al. Feasibility of second-generation ultrasound contrast media in the detection of active sacroilitis. Arthritis Rheum 2009;61:909-16.
32. Gutierrez M, Filippucci E, De Angelis R et al. A sonographic spectrum of psoriatic arthritis: "the five targets". Clin Rheumatol 2010;29:133-42.
33. D'Agostino MA, Said-Nahal R, Hacquard-Bouder C et al. Assessment of peripheral enthesitis in the spondyloarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum 2003;48:523-33. (Pubitemid 36278022)
34. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21. (Pubitemid 44025162)
35. Gladman DD, Mease PJ. Towards international guidelines for the management of psoriatic arthritis. J Rheumatol 2006;33:1228-30. (Pubitemid 44025130)
36. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1422-30. (Pubitemid 44025163)
37. Sarzi-Puttini P, Santandrea S, Boccassini L et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001;19(1 Suppl. 22):S17-20. (Pubitemid 32266548)
38. Helliwell PS, Taylor W; CASPAR Study Group. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions. J Rheumatol 2008;35:472-6. (Pubitemid 351374424)
39. Lie E, van der Heijde D, Uhlig T et al. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:671-6.
40. Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheum 2010;28(5 Suppl. 61):S132-7.
41. O'Brian WM, Van Scott EJ, Black RL et al. Clinical trial of amethopterin (methotrexate) in psoriatic and rheumatoid arthritis (preliminary report). Arthritis Rheum 1962;5:312.
42. Black RL, O'Brien WM, Vanscott EJ et al. Methotrexate therapy in psoriatic arthritis: double-blind study on 21 patients. JAMA 1964;189:743-7.
43. Willkens RF, Williams HJ, Ward JR et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81. (Pubitemid 14134777)
44. Scarpa R, Peluso R, Atteno M et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol 2008;27:823-6.
45. Kingsley GH, Packham JC, McHugh NJ et al. Methotrexate is not disease modifying in psoriatic arthritis: a new treatment paradigm is required. Rheumatology (Oxford) 2010;49(Suppl. 1):i1-i2.
46. Lacaillle D, Stein HB, Raboud J et al. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheumatol 2000;27:1922-7. (Pubitemid 30670487)
47. Spadaro A, Riccieri V, Sili-Scavalli A et al. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995;13:589-93.
48. Karanikolas GN, Arida K, Komninou E et al. Combination of adalimumab with cyclosporine- A against single therapy in refractory psoriatic arthritis: an interim analysis of an ongoing 12-month open, three-arm, randomized trial. Ann Rheum Dis 2009;65(Suppl. 3):138-9.
49. Clegg DO, Reda DJ, Mejias E et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum 1996;39:2013-20. (Pubitemid 127607904)
50. Kaltwasser JP, Nash P, Gladman D et al.; Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50. (Pubitemid 38725106)
51. Malesci D, Tirri R, Buono R et al. Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate. Clin Exp Rheumatol 2007;25:881-4. (Pubitemid 351166441)
52. Lee JC, Gladman DD, Schentag CT et al. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol 2001;7:160-5. (Pubitemid 32531027)
53. Zochling J, van der Heijde D, Dougados M et al. Current evidence for the management of ankylosing spondylitis. A systemic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
54. Rosenberg P, Urwitz H, Johannesson A et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007;46:995-8.
55. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008;7:563-72.
56. Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. Am J Med 2009;122: 1150.e1-9.
57. Kavanaugh A, Greenberg J, Lee S et al. Incidence of elevated liver enzymes (LFTs) in psoriatic arthritis (PsA) patients: effect of TNF-Inhibitors (TNF-I). Ann Rheum Dis 2010;69(Suppl. 3):579 (Abstract SAT0282).
58. Grismer LE, Gill SA, Harris MD. Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. J Clin Rheumatol 2001;7:224-7. (Pubitemid 32772081)
59. Alarcón GS. Psoriatic arthritis, methotrexate, and liver toxicity. J Clin Rheumatol 2001;7:213-4. (Pubitemid 32772079)
60. Taylor WJ, Korendowych E, Nash P et al. Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol 2008;35:1454-7. (Pubitemid 352000803)
61. Amital H, Arnson Y, Chodick G et al. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. Rheumatology (Oxford) 2009;48:1107-10.
62. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90. (Pubitemid 30487495)
63. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72. (Pubitemid 38924405)
64. Mease PJ, Kivitz AJ, Burch FX et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21.
65. Sterry W, Ortonne JP, Kirkham B et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomized double blind multicenter trial. BMJ 2010;340:c147.
66. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52:1227-36. (Pubitemid 40530131)
67. Antoni CE, Kavanaugh A, Van der Heijde D et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008;35:869-76. (Pubitemid 351747130)
68. Antoni C, Krueger GG, de Vlam K et al.; IMPACT 2 Study Group. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7. (Pubitemid 41113349)
69. Kavanaugh A, Krueger GG, Beutler A et al.; IMPACT 2 Study Group. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007;66:498-505. (Pubitemid 46580471)
70. Kavanaugh A, Antoni CE, Gladman D et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65:1038-43. (Pubitemid 44133266)
71. Mease PJ, Ory P, Sharp JT et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
72. Genovese MC, Mease PJ, Thomson GT et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34:1040-50. (Pubitemid 46774851)
73. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89. (Pubitemid 41447111)
74. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
75. Ortonne JP, Tasset C, Reich K et al. Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNF alpha monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: preliminary results from a double-blind placebo-controlled trial. J Am Acad Dermatol 2007;56(Suppl. 2):AB6.
76. Raffayova H, Kungurov N, Kubanova A et al. Infliximab plus methotrexate significantly improves rates of remission for methotrexate naïve psoriatic arthritis (PsA) patients compared to methotrexate alone: the RESPOND trial. Arthritis Rheum 2009;60(Suppl. 10):1256 (Abstract).
77. Raffayova H, Kungurov N, Kubanova A et al. Infliximab plus Methotrexate significantly improves synovitis and psoriatic lesions in methotrexate naïve psoriatic arthritis (PsA) patients: results of the RESPOND trial. Arthritis Rheum 2009;60(Suppl. 10):1780 (Abstract).
78. Atzeni F, Boccassini L, Antivalle M et al. Etanercept plus ciclosporine versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis 2011;70:712-4.
79. Saad AA, Symmons DP, Noyce PR et al. Risk and benefits of tumour necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and meta-analysis of randomized controlled trials. J Rheumatol 2008;35:883-90. (Pubitemid 351747132)
80. Delaunay C, Farrenq V, Marini-Portugal A et al. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005;32:2183-5. (Pubitemid 41587865)
81. Conti F, Ceccarelli F, Marocchi E et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007;66:1393-7. (Pubitemid 47492489)
82. Kraan MC, van Kuijk A, Dinant H et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002;46:2776-84. (Pubitemid 36118943)
83. Mease PJ, Gladman DD, Keystone EC; Alefacept in Psoriatic Arthritis Study Group. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006;54:1638-45.
84. Mease PJ, Reich K; Alefacept in Psoriatic Arthritis Study Group. Alefacept with methotrexate for treatment of psoriatic arthritis: open- label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009;60:402-11.
85. Mease P, Genovese M, Ritchlin C et al. Rituximab in psoriatic arthritis: results of an open label study. Ann Rheum Dis 2010;69(Suppl. 3):116 (Abstract).
86. Gottlieb A, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebocontrolled, crossover trial. Lancet 2009;373:633-40.
87. McQueen F, Lloyd R, Doyle A et al. Zolendronic acid does not reduce MRI erosive progression in PsA but may supress bone oedema: the Zolendronic Acid in Psoriatic Arthritis (ZAPA) Study. Ann Rheum Dis 2011;70:1091-4.
88. Lee S, Kavanaugh A. Biologic agents in rheumatology: safety considerations. Rheum Dis Clin N A 2006;32(Suppl. 1):3-10.
89. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 2008;37:251-5.
90. De Gannes GC, Ghoreishi M, Pope J et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31. (Pubitemid 46294587)
91. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007;56:2715-8. (Pubitemid 47237290)
92. Peno-Green L, Lluberas G, Kingsley T et al. Lung injury linked to etanercept therapy. Chest 2002;122:1858-60. (Pubitemid 35366106)
93. O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum 2006;55:978-81. (Pubitemid 44917474)
94. González-López MA, Blanco R, González-Vela MC et al. Development of sarcoidosis during etanercept therapy. Arthritis Rheum 2006;55:817-20.
95. Daïen CI, Monnier A, Claudepierre P et al. Sarcoid-like granulomatosis in patients treated with TNF blockers: 10 cases. Rheumatology (Oxford) 2009;48:883-6.
96. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-51. (Pubitemid 38725085)
97. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy. Analysis from a large US observational study. Arthritis Rheum 2009;56:2886-95. (Pubitemid 47502734)
98. Burmester GR, Mease P, Dijkmans BA et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68:1863-9.
99. Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997;336:1041-5. (Pubitemid 27163855)
100. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001;358:1042-5. (Pubitemid 32925124)
101. Amari W, Zeringue AL, McDonald JR et al. Non-melanoma and melanoma skin cancer risk in a national cohort of veterans with rheumatoid arthritis. Arthritis Rheum 2009;60(Suppl. 10):1379 (Abstract).
102. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, RA, and TNF inhibitors. J Rheumatol 2005;32:2130-5.
103. Cassell SE, Bieber JD, Rich P et al. The modified Nail Psorasis Severity Index: validation of an instrument to assess psoriatic nail involvement in pateints with psoriatic arthritis. J Rheumatol 2007;34:123-9. (Pubitemid 46106572)